GE HealthCare stock slips as Sofie Biosciences deal talks weigh on sentiment

Published on 09/14/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock closed at USD 63.93 on September 11, 2026, down 0.48 percent on the Nasdaq as investors assessed a potential USD 1 billion Sofie Biosciences acquisition. The shares trade about 24 percent below one valuation estimate and remain between their 12-month high and low.

Techniker bedient MRT-Scanner in hellem Krankenhaus-Untersuchungsraum mit Flurblick — GE HealthCare US36266G1076 zeigt einen modernen MRT-Scanner im hellen klinischen Krankenhaus mit Techniker, Illustration mit AI erstellt.

GE HealthCare Technologies Inc. stock (ISIN US36266G1076) closed at USD 63.93 on the Nasdaq on September 11, 2026, down 0.48 percent from the prior session as investors reacted to reports of a possible USD 1 billion acquisition of radiopharmaceutical developer Sofie Biosciences and a softer broader market tone.

Sofie Biosciences talks set the tone

According to Economic Times Health on September 14, 2026, GE HealthCare Technologies is in talks over a possible USD 1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, with the report citing people familiar with the matter and highlighting the strategic push into cancer scan chemicals.

As Pulse2 reported on September 14, 2026, the potential acquisition would be valued at about USD 1 billion and aims to expand GE HealthCare’s presence in radiopharmaceutical diagnostics beyond its traditional medical imaging equipment, although negotiations are ongoing and there is no guarantee a transaction will be completed.

Stock performance and valuation context

GE HealthCare stock finished the September 11, 2026 Nasdaq session at USD 63.93, with the closing price tied to regular trading hours at 4:00 p.m. Eastern and reflecting a modest decline of 0.48 percent versus the prior close per data cited in a recent MarketBeat-based update.

The same update noted that GE HealthCare Technologies Inc. (Nasdaq: GEHC) is trading between its 12-month low of USD 58.75 and its 12-month high of USD 89.77, giving investors a clear sense of the current price position within the recent range.

A valuation-focused commentary from GuruFocus, referenced in the September 13, 2026 review of GE HealthCare, pointed out that the shares around USD 63.93 were described as roughly a 24.4 percent discount to an intrinsic value estimate of USD 84.51, underlining that the stock trades materially below that particular fair-value model.

According to MarketScreener on September 14, 2026, the last closing price for GE HealthCare shares stood at USD 63.93, while the average analyst price target compiled in that overview was USD 82.50, implying an upside gap of about 29 percent to the consensus target.

In the same MarketScreener snapshot, the five-day performance was shown at minus 7.16 percent and the year-to-date performance at minus 22.06 percent, which places the current share level clearly below the start-of-year price and highlights how the stock has lagged broader healthcare peers in 2026 so far.

Analyst stance and strategic ambition

The MarketScreener data on September 14, 2026 indicated that the average recommendation on GE HealthCare stock from the analysts covered in that overview was in the Buy category, with a cluster of positive ratings supporting the view that the shares could recover toward the USD 82.50 average price target if execution on strategy and acquisitions proceeds as planned.

Separate commentary cited by Benzinga on September 13, 2026 noted that GE HealthCare stock has slumped by more than 32 percent from its all-time high and was up only about 1.48 percent from the day it went public, underscoring that despite the spin-off from General Electric the stock has so far delivered relatively modest net gains for long-term holders.

In operational terms, GE HealthCare is also pursuing growth away from its U.S. base. As Business Today reported on September 14, 2026, the company is targeting more than a doubling of exports from India and wants 75 percent of its local revenue there to come from products designed and manufactured in the country by 2030, a plan that could over time broaden margins and diversify revenue streams.

Stock level and investor view

GE HealthCare stock last closed at USD 63.93 on the Nasdaq on September 11, 2026, with the shares trading between a 12-month low of USD 58.75 and a 12-month high of USD 89.77 and sitting roughly one quarter below an intrinsic value estimate of USD 84.51 and around 29 percent below the USD 82.50 average analyst price target, a constellation that leaves investors weighing downside risks from the Sofie Biosciences talks against the potential upside from radiopharmaceutical growth and expanding emerging-market exports.